biOasis Provides Scientific Updates on Its Transcend Programs

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 12, 2015) - BIOASIS TECHNOLOGIES INC. (TSX VENTURE:BTI)(OTCQX:BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced results from its Her2+ brain tumor model with its lead therapeutic, MTfp-TZM. The company has also provided a scientific update relating to other programs.

The biOasis Neuro-Oncology Program

biOasis has completed efficacy and other tests using Her2+ brain tumor animal models using its lead BBB delivery vectors melanotransferrin (MTf) and melanotransferrin-peptide(MTfp) to deliver the anti-cancer drug, trastuzumab (TZM) across the blood-brain barrier (BBB). Fusion proteins comprised of the cancer drug trastuzumab (TZM or Herceptin) and MTf (MTf-TZM) or MTfp (MTfp-TZM) were used. The purpose of these studies was to answer specific questions and provide data relating to taking MTfp-TZM into clinical trials. As a result of the combined studies and with the benefit of the full collection of data, the biOasis Board of Directors supports moving MTfp-TZM to an IND and into clinical trials.

The recent results revealed that MTfp-TZM showed increased activity against Her2+ brain tumors when compared to other Transcend/trastuzumab conjugates that biOasis has previously tested. MTfp-TZM reduced the size and number of brain tumors in the animal models and showed improved activity levels outside the brain compared to TZM alone. Statistically significant increased animal survival rates were also observed compared to the controls. An additional dose titration study confirmed tolerance at levels equal to that of current dosing in humans.

Commented CEO, Rob Hutchison, "We're very pleased with the latest results of the MTf-and MTfp-trastuzumab studies. MTfp-TZM met or exceeded our objectives with the key data confirming the enhanced activity of the fusion protein and as a result, our Board of Directors has placed a high priority on moving MTfp-TZM into the clinic. Until submissions are made to clinical regulators and to scientific publications, biOasis will not be releasing quantitative data from the studies, but may do so at an appropriate time in the future."

The biOasis Lysosomal Storage Disease (LSD) Program

In late 2014, biOasis initiated a study using an animal model of Lysosomal Storage Disease with Dr. Maurizio Scarpa and the Brains for Brain Foundation in Padova, Italy. The purpose of the study is to investigate the ability of biOasis' Transcend BBB transport technology to deliver to the central nervous system the therapeutic enzyme required to correct the neurological disorder Mucopolysaccharidosis type II or Hunter syndrome. The study aims to determine whether a therapeutic quantity of idursulphase (I2S) can be delivered to the brain using biOasis's Transcend fusion proteins, MTf-I2S and the MTfp-I2S, and whether the fusion proteins can restore normal function after intravenous administration.

The company is pleased to report that the portion of the study performed in live animals is now complete and that the histopathology analyses are currently underway. Early results indicate that the animals given the fusion protein MTfp-I2S had levels of glycosaminoglycan similar to those seen in the liver of wild-type (normal) mice. Glycosaminoglycan levels are elevated in liver cell lysosomes of MPS II diseased mice.

The biOasis siRNA Program

On March 16, 2015, biOasis announced the results of an ischemic stroke model performed using the Transcend peptide carrier, MTfp coupled to a siRNA. In this study, the company demonstrated that the MTfp-siRNA therapeutic was successfully transported across the BBB, reduced the volume of the brain infarct, and improved overall brain function as determined by neurological scoring.

The ischemic stroke model was undertaken as a "proof-of-concept" study due to the clear data readout this model provides. The goal of this study was to provide a therapeutic efficacy study to support licensing of biOasis' vector MTfp to interested gene therapy companies for the treatment of CNS diseases such as Parkinson's disease and amyotrophic lateral sclerosis (ALS).

The biOasis-Medimmune Neuropathic Pain Program

Studies conducted by MedImmune, LLC. have produced data that illustrate certain desirable characteristics of the biOasis peptide carrier, MTfp. To validate the peptide (MTfp) licensing model, MedImmune was provided with the amino acid sequence of MTfp. Using the MTfp sequence, MedImmune designed and manufactured a fusion protein comprised of MTfp coupled to an antibody that targets a pain receptor in the brain. In an animal model, the fusion successfully crossed the BBB and also showed greater pain reduction than the currently used therapeutic.

Up to 5% of the injected dose of the MTfp-antibody fusion entered the brain and showed peak transport at 24 hours. Active transport into the brain of between 3-4% continued for more than 12 days. In contrast, the full-length MTf-antibody fusion showed a peak of brain exposure at approximatively 2 hrs, which decreased afterwards, exhibiting a half-life in plasma of 5 days. Importantly, administration of either MTf-antibody or MTfp-antibody fusion or conjugate produced a greater degree of analgesia in the neuropathic pain model when compared to administration of the antibody alone. Analgesia is dependent on the antibody entering the CNS.

Stated CEO Rob Hutchison, "These results with MedImmune are of great importance for biOasis and its licensing business model. We now know that the MTfp amino acid sequence can be provided to a licensee and the licensee will be able to build the sequence into its therapeutics with relative ease and with low manufacturing costs. In addition, the increased half-life observed with the MTfp transport vector results in a much higher exposure of the therapeutic in the brain, a key consideration for our potential licensing partners."

About Transcend

Transcend is biOasis' proprietary platform for the delivery of therapeutics across the BBB to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The BBB represents the single greatest challenge in treating neurological disorders. The ability to effectively and selectively breech the BBB offers the opportunity for biOasis to deliver therapeutics into the brain. Transcend was originally based on MTf (melanotransferrin or p97) where the full-length protein was conjugated to therapeutic molecules. Recently biOasis identified a family of peptides within MTf that facilitates receptor-mediated transcytosis. The lead peptide carrier was used in the work reported above.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"